Elizabeth Covington

Densely integrated array of chemiresistor vapor sensors with electron-beam patterned monolayer-protected gold nanoparticle interface films

Use of electron-beam induced crosslinking to pattern films of monolayer-protected gold nanoparticles (MPNs) onto a chemiresistor (CR) sensor array is described. Each of the four CRs comprises a 100 µm(2) set of interdigital electrodes (IDEs) with 100 nm widths and spaces, separated from adjacent devices by 4 µm. Films of four MPNs, each with a different thiolate monolayer, were successively patterned on the IDEs. Vapor exposures yield rapid, reversible changes in CR resistances and differential vapor sensitivities comparable to those reported for larger CRs with unpatterned MPN films. The array response patterns facilitate vapor discrimination. This is the smallest MPN-coated CR array yet reported. The advantages of using such an array as the detector in microfabricated gas chromatographic analyzers are considered.

Characterization of Dense Arrays of Chemiresistor Vapor Sensors with Submicrometer Features and Patterned Nanoparticle Interface Layers

The performance of arrays of small, densely integrated chemiresistor (CR) vapor sensors with electron-beam patterned interface layers of thiolate-monolayer-protected gold nanoparticles (MPNs) is explored. Each CR in the array consists of a 100-μm(2) interdigital electrode separated from adjacent devices by 4 μm. Initial studies involved four separate arrays, each containing four CRs coated with one of four different MPNs, which were calibrated with five vapors before and after MPN-film patterning. MPNs derived from n-octanethiol (C8), 4-(phenylethynyl)-benzenethiol (DPA), 6-phenoxyhexane-1-thiol (OPH), and methyl-6-mercaptohexanoate (HME) were tested. Parallel calibrations of MPN-coated thickness-shear-mode resonators (TSMR) were used to derive partition coefficients of unpatterned films and to assess transducer-dependent factors affecting responses. A 600-μm(2) 4-CR array with four different patterned MPN interface layers, in which the MPN derived from 7-hydroxy-7,7-bis(trifluoro-methyl)heptane-1-thiol (HFA) was substituted for HME, was then characterized. This is the smallest multi-MPN array yet reported. Reductions in the diversity of the collective response patterns are observed with the patterned films, but projected vapor discrimination rates remain high. The use of such arrays as ultralow-dead-volume detectors in microscale gas chromatographic analyzers is discussed.

Improving treatment plan evaluation with automation

The goal of this work is to evaluate the effectiveness of Plan‐Checker Tool (PCT) which was created to improve first‐time plan quality, reduce patient delays, increase the efficiency of our electronic workflow, and standardize and automate the physics plan review in the treatment planning system (TPS). PCT uses an application programming interface to check and compare data from the TPS and treatment management system (TMS). PCT includes a comprehensive checklist of automated and manual checks that are documented when performed by the user as part of a plan readiness check for treatment. Prior to and during PCT development, errors identified during the physics review and causes of patient treatment start delays were tracked to prioritize which checks should be automated. Nineteen of 33 checklist items were automated, with data extracted with PCT. There was a 60% reduction in the number of patient delays in the six months after PCT release. PCT was successfully implemented for use on all external beam treatment plans in our clinic. While the number of errors found during the physics check did not decrease, automation of checks increased visibility of errors during the physics check, which led to decreased patient delays. The methods used here can be applied to any TMS and TPS that allows queries of the database. PACS number(s): 87.55.‐x, 87.55.N‐, 87.55.Qr, 87.55.tm, 89.20.BbThe goal of this work is to evaluate the effectiveness of Plan-Checker Tool (PCT) which was created to improve first-time plan quality, reduce patient delays, increase the efficiency of our electronic workflow, and standardize and automate the physics plan review in the treatment planning system (TPS). PCT uses an application programming interface to check and compare data from the TPS and treatment management system (TMS). PCT includes a comprehensive checklist of automated and manual checks that are documented when performed by the user as part of a plan readiness check for treatment. Prior to and during PCT development, errors identified during the physics review and causes of patient treatment start delays were tracked to prioritize which checks should be automated. Nineteen of 33 checklist items were automated, with data extracted with PCT. There was a 60% reduction in the number of patient delays in the six months after PCT release. PCT was successfully implemented for use on all external beam treatment plans in our clinic. While the number of errors found during the physics check did not decrease, automation of checks increased visibility of errors during the physics check, which led to decreased patient delays. The methods used here can be applied to any TMS and TPS that allows queries of the database. PACS number(s): 87.55.-x, 87.55.N-, 87.55.Qr, 87.55.tm, 89.20.Bb.

CMOS Monolithic Nanoparticle-Coated Chemiresistor Array for Micro-Scale Gas Chromatography

Miniaturized detector arrays are critical to reducing size and maintaining measurement quality of integrated micro-gas chromatographs (μGC) used for the analysis of complex vapor mixtures. This paper presents an array of chemiresistors (CRs) with monolayer-protected gold nanoparticle films formed on the surface of a complementary-metal-oxide semiconductor (CMOS) readout chip, featuring high-resolution resistance measurement with adaptive cancellation of baseline resistance. The 8-channel readout circuit occupies 2.2 × 2.2 mm2 in 0.5 μm CMOS and consumes 66 μW per channel from a 3.3-V power supply. It achieves a worst-case resolution of 125 ppm over a broad baseline resistance range of 60 kΩ to 10 MΩ, equivalent to 122 dB dynamic range. Implementation of the CMOS monolithic detector array is discussed, and preliminary measurement results using chamber exposures to several vapors are presented. Eventual integration into a μGC is discussed.

Revisiting fetal dose during radiation therapy: evaluating treatment techniques and a custom shield

To create a comprehensive dataset of peripheral dose (PD) measurements from a new generation of linear accelerators with and without the presence of a newly designed fetal shield, PD measurements were performed to evaluate the effects of depth, field size, distance from the field edge, collimator angle, and beam modifiers for common treatment protocols and modalities. A custom fetal lead shield was designed and made for our department that allows external beam treatments from multiple angles while minimizing the need to adjust the shield during patient treatments. PD measurements were acquired for a comprehensive series of static fields on stack of Solid Water. Additionally, PDs from various clinically relevant treatment scenarios for pregnant patients were measured using an anthropomorphic phantom that was abutted to a stack of Solid Water. As expected, the PD decreased as the distance from the field edge increased and the field size decreased. On average, a PD reduction was observed when a 90° collimator rotation was applied and/or when the tertiary MLCs and jaws defined the field aperture. However, the effect of the collimator rotation (90° versus 0°) in PD reduction was not found to be clinically significant when the tertiary MLCs were used to define the field aperture. In the presence of both the MLCs and the fetal shield, the PD was reduced by 58% at a distance of 10 cm from the field edge. The newly designed fetal shield may effectively reduce fetal dose and is relatively easy to setup. Due to its design, we are able to use a broad range of treatment techniques and beam angles. We believe the acquired comprehensive PD dataset collected with and without the fetal shield will be useful for treatment teams to estimate fetal dose and help guide decisions on treatment techniques without the need to perform pretreatment phantom measurements. PACS numbers: 87.53.Bn, 87.55.D-, 87.55.N.To create a comprehensive dataset of peripheral dose (PD) measurements from a new generation of linear accelerators with and without the presence of a newly designed fetal shield, PD measurements were performed to evaluate the effects of depth, field size, distance from the field edge, collimator angle, and beam modifiers for common treatment protocols and modalities. A custom fetal lead shield was designed and made for our department that allows external beam treatments from multiple angles while minimizing the need to adjust the shield during patient treatments. PD measurements were acquired for a comprehensive series of static fields on a stack of Solid Water. Additionally, PDs from various clinically relevant treatment scenarios for pregnant patients were measured using an anthropomorphic phantom that was abutted to a stack of Solid Water. As expected, the PD decreased as the distance from the field edge increased and the field size decreased. On average, a PD reduction was observed when a 90° collimator rotation was applied and/or when the tertiary MLCs and jaws defined the field aperture. However, the effect of the collimator rotation (90° versus 0°) in PD reduction was not found to be clinically significant when the tertiary MLCs were used to define the field aperture. In the presence of both the MLCs and the fetal shield, the PD was reduced by 58% at a distance of 10 cm from the field edge. The newly designed fetal shield may effectively reduce fetal dose and is relatively easy to setup. Due to its design, we are able to use a broad range of treatment techniques and beam angles. We believe the acquired comprehensive PD dataset collected with and without the fetal shield will be useful for treatment teams to estimate fetal dose and help guide decisions on treatment techniques without the need to perform pretreatment phantom measurements. PACS number(s): 87.53.Bn, 87.55.D‐, 87.55.N

SafetyNet: Streamlining and Automating QA in radiotherapy

Proper quality assurance (QA) of the radiotherapy process can be time‐consuming and expensive. Many QA efforts, such as data export and import, are inefficient when done by humans. Additionally, humans can be unreliable, lose attention, and fail to complete critical steps that are required for smooth operations. In our group we have sought to break down the QA tasks into separate steps and to automate those steps that are better done by software running autonomously or at the instigation of a human. A team of medical physicists and software engineers worked together to identify opportunities to streamline and automate QA. Development efforts follow a formal cycle of writing software requirements, developing software, testing and commissioning. The clinical release process is separated into clinical evaluation testing, training, and finally clinical release. We have improved six processes related to QA and safety. Steps that were previously performed by humans have been automated or streamlined to increase first‐time quality, reduce time spent by humans doing low‐level tasks, and expedite QA tests. Much of the gains were had by automating data transfer, implementing computer‐based checking and automation of systems with an event‐driven framework. These coordinated efforts by software engineers and clinical physicists have resulted in speed improvements in expediting patient‐sensitive QA tests. PACS number(s): 87.55.Ne, 87.55.Qr, 87.55.tg, 87.55.tmProper quality assurance (QA) of the radiotherapy process can be time-consuming and expensive. Many QA efforts, such as data export and import, are inefficient when done by humans. Additionally, humans can be unreliable, lose attention, and fail to complete critical steps that are required for smooth operations. In our group we have sought to break down the QA tasks into separate steps and to automate those steps that are better done by software running autonomously or at the instigation of a human. A team of medical physicists and software engineers worked together to identify opportunities to streamline and automate QA. Development efforts follow a formal cycle of writing software requirements, developing software, testing and commissioning. The clinical release process is separated into clinical evaluation testing, training, and finally clinical release. We have improved six processes related to QA and safety. Steps that were previously performed by humans have been automated or streamlined to increase first-time quality, reduce time spent by humans doing low-level tasks, and expedite QA tests. Much of the gains were had by automating data transfer, implementing computer-based checking and automation of systems with an event-driven framework. These coordinated efforts by software engineers and clinical physicists have resulted in speed improvements in expediting patient-sensitive QA tests. PACS number(s): 87.55.Ne, 87.55.Qr, 87.55.tg, 87.55.tm.

Characterization of room temperature metal microbolometers near the metal-insulator transition regime for scanning thermal microscopy

Metal microbolometers, used in scanning thermal microscopy, were microfabricated from <20?nm titanium thin films on SiO2/Si3N4/SiO2 cantilevers. These thin films are near the metal-insulator transition regime such that as the film thickness decreases—the resistance increases and the current-voltage characteristics cross over from sublinear to superlinear. In addition, the temperature coefficient of resistance transitions from positive to negative before it plateaus at a negative value. Thin titanium films exhibit negative temperature coefficient of resistance as high as ?0.0067/K which is higher than that of bulk titanium films.

Technical Report: Evaluation of peripheral dose for flattening filter free photon beams

PURPOSE To develop a comprehensive peripheral dose (PD) dataset for the two unflattened beams of nominal energy 6 and 10 MV for use in clinical care. METHODS Measurements were made in a 40 × 120 × 20 cm(3) (width × length × depth) stack of solid water using an ionization chamber at varying depths (dmax, 5, and 10 cm), field sizes (3 × 3 to 30 × 30 cm(2)), and distances from the field edge (5-40 cm). The effects of the multileaf collimator (MLC) and collimator rotation were also evaluated for a 10 × 10 cm(2) field. Using the same phantom geometry, the accuracy of the analytic anisotropic algorithm (AAA) and Acuros dose calculation algorithm was assessed and compared to the measured values. RESULTS The PDs for both the 6 flattening filter free (FFF) and 10 FFF photon beams were found to decrease with increasing distance from the radiation field edge and the decreasing field size. The measured PD was observed to be higher for the 6 FFF than for the 10 FFF for all field sizes and depths. The impact of collimator rotation was not found to be clinically significant when used in conjunction with MLCs. AAA and Acuros algorithms both underestimated the PD with average errors of -13.6% and -7.8%, respectively, for all field sizes and depths at distances of 5 and 10 cm from the field edge, but the average error was found to increase to nearly -69% at greater distances. CONCLUSIONS Given the known inaccuracies of peripheral dose calculations, this comprehensive dataset can be used to estimate the out-of-field dose to regions of interest such as organs at risk, electronic implantable devices, and a fetus. While the impact of collimator rotation was not found to significantly decrease PD when used in conjunction with MLCs, results are expected to be machine model and beam energy dependent. It is not recommended to use a treatment planning system to estimate PD due to the underestimation of the out-of-field dose and the inability to calculate dose at extended distances due to the limits of the dose calculation matrix.

Nanoscale chemiresistor arrays with patterned nanoparticle interface layers for micro gas chromatography

Chemiresistor (CR) arrays with nanoscale electrode features and crosslinked thiolate-monolayer-protected gold nanoparticle (MPN) sensing layers were fabricated and characterized. These arrays, intended for ultimate use as detectors in a micro-scale gas chromatograph, employ interdigital electrodes (10 µm finger length with 100 nm width and spacing) patterned by electron-beam lithography. Films of different MPNs were sequentially deposited on the electrodes and crosslinked by electron-beam exposure. Responses to vapors were compared with those from a reference array with uncrosslinked films. Differences in sensitivities and response patterns between crosslinked and uncrosslinked arrays with the same MPN films are rationalized in terms of structural changes in the MPN ligands and related changes in vapor sorption by the films.

Electrical noise in gold nanoparticle chemiresistors

We studied electrical noise of gold nanoparticle chemical sensors with the intent of improving their limit of detection. All the sensors exhibit 1/f-type noise at low frequencies. The magnitude of the noise is found to be strongly dependent on the thickness of the films. The sensors containing a single monolayer of nanoparticles had the highest resistance and the worst noise performance. By making the films thicker, we were able to lower the 1/f noise by five orders of magnitude. The nanoparticle deposition of the thicker films was done with a micro-dispensing system, which resulted in highly non-uniform, coffee-stain patterned films. To get films of different thicknesses, we varied the number of drops deposited on each sensor. The noise prefactor extracted from different devices scaled linearly with the resistance of sensors. The effects of electron beam cross-linking were also studied and found to lower the noise of the sensors.